Liofilchem® Ceftolozane-tazobactam C/T, Antimicrobial Susceptibility Discs, 40 µg

Liofilchem® Ceftolozane-Tazobactam Discs (40 µg) are high-quality, ready-to-use antimicrobial susceptibility testing (AST) discs formulated for the Kirby-Bauer disk diffusion method on Mueller-Hinton agar. Each disc is impregnated with a fixed 2:1 ratio of Ceftolozane (20 µg) and Tazobactam (10 µg) to achieve a total potency of 40 µg. This combination is a β-lactam/β-lactamase inhibitor specifically designed to target multidrug-resistant (MDR) Gram-negative bacteria, including Pseudomonas aeruginosa and extended-spectrum β-lactamase (ESBL) producing Enterobacterales. Manufactured under ISO 9001 and ISO 13485 standards, these discs offer exceptional reliability in routine clinical diagnostics and advanced resistance profiling.

Key Features

• Fixed dual-agent combination: 20 µg Ceftolozane + 10 µg Tazobactam per disc for enhanced efficacy against β-lactamase-producing bacteria.
• MDR pathogen coverage: Active against Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and other ESBL-producing strains.
• CLSI/EUCAST compliant: Supports standardized interpretation in clinical microbiology labs.
• Sterile and shelf-stable: Individually packaged or in cartridges to maintain potency and prevent contamination.
• Color-coded labeling: Simplifies identification in high-volume workflows.

Applications and Use Cases

1. Clinical Microbiology

Used in hospital and diagnostic laboratories to:

• Determine susceptibility of MDR Gram-negative bacteria, especially:
  • Carbapenem-resistant Pseudomonas aeruginosa
  • ESBL-producing Enterobacterales
• Guide targeted therapy for:
  • Complicated intra-abdominal infections (cIAIs)
  • Complicated urinary tract infections (cUTIs), including pyelonephritis
  • Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)

2. Antimicrobial Stewardship

• Supports effective decision-making in high-risk, critical-care patients.
• Minimizes reliance on last-resort antibiotics like colistin by offering an alternative with improved safety and efficacy.

3. Research and Surveillance

• Analyze β-lactam/β-lactamase inhibitor resistance mechanisms.
• Monitor emerging resistance in clinical and environmental Gram-negative isolates.
• Contribute to global surveillance studies of MDR pathogen prevalence.

Use Instructions

1. Prepare Mueller-Hinton agar plates using standard laboratory procedures.
2. Standardize bacterial inoculum to 0.5 McFarland turbidity.
3. Inoculate the agar surface evenly with the test strain.
4. Apply the Ceftolozane-Tazobactam disc (40 µg) using sterile forceps or a disc dispenser.
5. Incubate at 35 ± 2 °C for 16–18 hours.
6. Measure the inhibition zone in millimeters.
7. Interpret results using the most current CLSI or EUCAST breakpoints specific to P. aeruginosa and Enterobacterales.

Storage and Shelf Life

• Storage Conditions: 2–8 °C (refrigerated) with desiccant.
• Shelf Life: Typically 2–3 years from manufacturing date when stored unopened and as recommended.

Liofilchem® Ceftolozane-Tazobactam C/T Discs (40 µg) provide a powerful and precise diagnostic tool for detecting susceptibility to one of the newest β-lactam/β-lactamase inhibitor combinations. These discs are essential for combating multidrug-resistant Gram-negative infections, especially in critically ill patients. Their accuracy, stability, and adherence to international AST guidelines make them a preferred choice in modern clinical microbiology, surveillance programs, and antimicrobial resistance research.